Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus letrozole versus placebo plus letrozole in ER-positive, HER2-negative advanced breast cancer
2012-004601-27Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Palbociclib plus letrozole with Placebo plus letrozole (2 arms). Primary endpoint: Progression-Free Survival. Started Apr 2013; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-004601-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004601-27.